JP7512278B2 - 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定 - Google Patents

肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定 Download PDF

Info

Publication number
JP7512278B2
JP7512278B2 JP2021530259A JP2021530259A JP7512278B2 JP 7512278 B2 JP7512278 B2 JP 7512278B2 JP 2021530259 A JP2021530259 A JP 2021530259A JP 2021530259 A JP2021530259 A JP 2021530259A JP 7512278 B2 JP7512278 B2 JP 7512278B2
Authority
JP
Japan
Prior art keywords
methylation
marker
max
dna
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513658A (ja
JPWO2020112869A5 (enExample
Inventor
アラーウィ，ハティム
ピー． リドガード，グラハム
ギアクモプロス，マリア
エー． アールクイスト，デビッド
アール． テイラー，ウィリアム
マホーニー，ダグラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of JP2022513658A publication Critical patent/JP2022513658A/ja
Publication of JPWO2020112869A5 publication Critical patent/JPWO2020112869A5/ja
Priority to JP2024103130A priority Critical patent/JP2024123233A/ja
Application granted granted Critical
Publication of JP7512278B2 publication Critical patent/JP7512278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021530259A 2018-11-27 2019-11-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定 Active JP7512278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103130A JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771965P 2018-11-27 2018-11-27
US62/771,965 2018-11-27
PCT/US2019/063401 WO2020112869A1 (en) 2018-11-27 2019-11-26 Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103130A Division JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定

Publications (3)

Publication Number Publication Date
JP2022513658A JP2022513658A (ja) 2022-02-09
JPWO2020112869A5 JPWO2020112869A5 (enExample) 2022-12-06
JP7512278B2 true JP7512278B2 (ja) 2024-07-08

Family

ID=70853661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530259A Active JP7512278B2 (ja) 2018-11-27 2019-11-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定
JP2024103130A Pending JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103130A Pending JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定

Country Status (10)

Country Link
US (1) US20220136058A1 (enExample)
EP (1) EP3886878A4 (enExample)
JP (2) JP7512278B2 (enExample)
KR (1) KR20210099044A (enExample)
CN (1) CN113423410A (enExample)
AU (1) AU2019389008A1 (enExample)
BR (1) BR112021009795A2 (enExample)
CA (1) CA3119329A1 (enExample)
MX (1) MX2021005963A (enExample)
WO (1) WO2020112869A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255198A4 (en) 2008-02-15 2011-05-25 Mayo Foundation DETECTION OF NEOPLASM
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
WO2015153284A1 (en) 2014-03-31 2015-10-08 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
CA3002196C (en) 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
US10385406B2 (en) 2016-05-05 2019-08-20 Exact Sciences Development Company, Llc Detection of lung neoplasia by analysis of methylated DNA
KR102892245B1 (ko) 2017-01-27 2025-11-27 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 메틸화된 dna 분석에 의한 결장 신조직형성의 검출
WO2019108626A1 (en) 2017-11-30 2019-06-06 Mayo Foundation For Medical Education And Research Detecting breast cancer
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US20220403471A1 (en) * 2019-08-27 2022-12-22 Exact Sciences Corporation Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
CN114651070A (zh) 2019-09-16 2022-06-21 精密科学公司 结构和温度依赖性瓣状核酸内切酶底物
CA3154354A1 (en) 2019-10-31 2021-05-06 William R. Taylor Detecting ovarian cancer
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
US12467096B2 (en) 2020-05-15 2025-11-11 Universal Diagnostics, S.A. Methods and systems for identifying methylation biomarkers
CN115997035A (zh) 2020-06-30 2023-04-21 通用诊断股份公司 用于检测多种癌症类型的系统和方法
EP3945135A1 (en) * 2020-07-27 2022-02-02 Les Laboratoires Servier Biomarkers for diagnosing and monitoring lung cancer
WO2022165247A1 (en) * 2021-01-29 2022-08-04 Mayo Foundation For Medical Education And Research Detecting the presence or absence of multiple types of cancer
CN115505640A (zh) * 2021-06-22 2022-12-23 上海鹍远生物科技股份有限公司 检测肺癌的dna甲基化标志物及应用
CN115725734B (zh) * 2022-08-10 2023-10-13 人和未来生物科技（长沙）有限公司 Znf781基因在制备宫颈癌诊断试剂中的应用
CN117683877A (zh) * 2023-12-19 2024-03-12 上海交通大学医学院 一种诊断或治疗免疫系统疾病的生物标志物或靶点

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064702A1 (ja) 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264659A1 (en) * 2006-05-11 2007-11-15 Sungwhan An Lung cancer biomarker discovery
WO2010074924A1 (en) * 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
JP2014531213A (ja) * 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
WO2013070950A1 (en) * 2011-11-08 2013-05-16 University Of Southern California Identification of a dna methylation marker for blood-based detection of ovarian cancer
US9546403B1 (en) * 2011-12-14 2017-01-17 University Of Utah Research Foundation Substrate for methylated DNA testing
US10465248B2 (en) * 2014-12-12 2019-11-05 Exact Sciences Development Company, Llc Method of characterizing ZDHHC1 DNA
JP6877704B2 (ja) * 2015-11-16 2021-05-26 公立大学法人名古屋市立大学 膵臓癌の検出のための方法及びキット
US10385406B2 (en) * 2016-05-05 2019-08-20 Exact Sciences Development Company, Llc Detection of lung neoplasia by analysis of methylated DNA
AU2017281099A1 (en) * 2016-06-21 2019-01-03 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
WO2018017740A1 (en) * 2016-07-19 2018-01-25 Exact Sciences Development Company, Llc Methylated control dna

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064702A1 (ja) 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BMC Medical Genomics，2014年，7:18，p.1-8，http://www.biomedcentral.com/1755-8794/7/18
Journal of Pathology，2015年，Vol.235，p.397-407，DOI: 10.1002/path.4469
PLoS ONE，2011年，Vol.6, Issue 12，e28141
日本分子腫瘍マーカー研究会誌，2012年，Vol.27，p.65-66，doi.org/10.11241.jsmtmr.27.65
日本分子腫瘍マーカー研究会誌，2014年，Vol.29，p.22-23，doi.org/10.11241.jsmtmr.29.22

Also Published As

Publication number Publication date
BR112021009795A2 (pt) 2021-08-17
CA3119329A1 (en) 2020-06-04
EP3886878A1 (en) 2021-10-06
JP2022513658A (ja) 2022-02-09
JP2024123233A (ja) 2024-09-10
US20220136058A1 (en) 2022-05-05
KR20210099044A (ko) 2021-08-11
EP3886878A4 (en) 2022-11-02
WO2020112869A1 (en) 2020-06-04
AU2019389008A1 (en) 2021-06-03
CN113423410A (zh) 2021-09-21
MX2021005963A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7512278B2 (ja) 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定
JP7670662B2 (ja) メチル化ｄｎａの分析による腫瘍の検出
US11028447B2 (en) Detection of neoplasia by analysis of methylated dna
JP7293109B2 (ja) 肝細胞癌の検出
JP7356349B2 (ja) 前立腺癌検出
US20220403471A1 (en) Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
KR20250171455A (ko) 메틸화된 dna 분석에 의한 결장 신조직형성의 검출

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240626